Full application: stand-alone application under Article 8(3)
A full application under Article 8(3) of Directive 2001/83/EC is a stand-alone dossier with the applicant's own quality, pre-clinical and clinical data.
Also known as: stand-alone application, Article 8(3) application, full dossier, complete application
3 min readUpdated
Reviewed by Gosia Luksza, CEO at Regunaut
At a glance
- Legal basis
- Article 8(3) of Directive 2001/83/EC; Article 6 of Regulation (EC) No 726/2004
- Data
- Own pharmaceutical, pre-clinical and clinical data; literature only as support
- Variant
- Mixed application under Annex I, Part II, section 7
- Assessment
- 210 active days plus clock-stops
How it works
Article 8(3) of Directive 2001/83/EC lists the particulars and documents that must accompany a marketing authorisation application, including the results of pharmaceutical (physico-chemical, biological or microbiological) tests, pre-clinical (toxicological and pharmacological) tests and clinical trials. An application that contains all of them, generated by or for the applicant, is called a full, complete or stand-alone application. Article 6 of Regulation (EC) No 726/2004 applies the same content requirements to centralised applications. It is the default legal basis: Articles 10, 10a, 10b and 10c are derogations or special cases that allow parts of the data to be replaced or shared.
The route is the only one available for a new active substance, since there is nothing to refer to, but it is not limited to new substances. A company can file a full application for a known substance when no abridged route is open or wanted: while the originator's data exclusivity is still running, when the product differs too much from any reference product, or when the company prefers to own its data. Annex I, Part II, section 7 of the Directive provides for mixed applications, in which Modules 4 and 5 combine the applicant's own limited non-clinical or clinical studies with bibliographical references. A mixed application is still an Article 8(3) application, and the applicant must justify why literature is sufficient for the parts it does not cover with its own data. Published literature can also be submitted as supportive data in any full application.
The dossier follows the Common Technical Document, with all five modules, and comes with the obligations that attach to a new product: a risk management plan, an agreed paediatric investigation plan or waiver where Regulation (EC) No 1901/2006 requires one, and an environmental risk assessment. In return, a product authorised on a complete dossier can serve as a reference product for later generics, and where it starts a new global marketing authorisation its data are protected by eight years of data exclusivity and ten of market protection. A fixed combination under Article 10b is also filed with a complete dossier, and an informed consent application under Article 10c uses one with the holder's permission.
What goes wrong
Choosing a mixed dossier to avoid studies the assessors consider necessary, so that major objections arrive at Day 120; filing under Article 8(3) a dossier that is in substance bibliographic, or under Article 10a one that contains own studies, and being asked to change the legal basis at validation; forgetting that the paediatric and risk management requirements apply to a full application for an old substance as they do to a new one; and assuming that own data on a known substance block generics of the original product, when they only protect the new dossier. Fees are also the highest of any application type at most authorities.
Timing
A full application is assessed in 210 active days in the national, decentralised and centralised procedures, with clock-stops for the applicant's responses. In the centralised procedure the Commission decision follows the CHMP opinion. Data exclusivity and market protection for a product that starts a new global marketing authorisation run from that first authorisation.
What teams do with it in Regunaut
Jobs in the platform that turn on Full application, each part of a wider workflow.
- Workbench quick task · SubmissionsReview dossier readinessFind missing evidence and prioritise gaps before submission.Part of Where to expand next
- Workbench quick task · CMCOutline a stability programmeIdentify study conditions, time points, and product-specific inputs.Part of Variations & CMC changes
Full application: common questions
What is the difference between a full application and a generic application?
A full application under Article 8(3) contains the applicant's own quality, pre-clinical and clinical data and refers to no other product's dossier. A generic application under Article 10(1) contains quality data and a bioequivalence study and relies on the reference product for safety and efficacy, which is only possible once the reference product's eight years of data exclusivity have ended.
What is a mixed application?
It is a full application under Article 8(3) in which the non-clinical or clinical modules combine the applicant's own studies with published literature. Annex I, Part II, section 7 of Directive 2001/83/EC provides for it. It differs from a well-established use application, where literature alone carries the whole demonstration of safety and efficacy.
Can you file a full application for a known active substance?
Yes. Article 8(3) is open to any product, and companies use it for known substances when an abridged route is unavailable, for example during the originator's data exclusivity, or when they want their own data. The application does not affect generics of the original product, which continue to rely on that product's dossier.
Sources
- EUR-Lex: Directive 2001/83/EC on the Community code relating to medicinal products for human use
- EUR-Lex: Regulation (EC) No 726/2004 laying down Union procedures for the authorisation and supervision of medicinal products
- European Commission: EudraLex Volume 2, Notice to applicants for medicinal products for human use